ADC Therapeutics S.A.
ADCT · NYSE
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $16 | $19 | $23 | $17 |
| % Growth | -12.8% | -18.2% | 36.2% | – |
| Cost of Goods Sold | $1 | $1 | $2 | $1 |
| Gross Profit | $15 | $18 | $21 | $16 |
| % Margin | 92.7% | 95.6% | 91.1% | 91.9% |
| R&D Expenses | $27 | $30 | $29 | $27 |
| G&A Expenses | $14 | $15 | $10 | $15 |
| SG&A Expenses | $19 | $19 | -$1 | $21 |
| Sales & Mktg Exp. | $5 | $4 | -$11 | $6 |
| Other Operating Expenses | $0 | $13 | $21 | $0 |
| Operating Expenses | $46 | $62 | $49 | $48 |
| Operating Income | -$31 | -$44 | -$28 | -$32 |
| % Margin | -188.5% | -234.3% | -123.6% | -191.8% |
| Other Income/Exp. Net | -$10 | -$11 | -$10 | $1 |
| Pre-Tax Income | -$41 | -$55 | -$38 | -$31 |
| Tax Expense | $0 | $1 | $0 | -$0 |
| Net Income | -$41 | -$57 | -$39 | -$31 |
| % Margin | -249.4% | -300.7% | -167.6% | -181.7% |
| EPS | -0.3 | -0.5 | -0.36 | -0.29 |
| % Growth | 40% | -38.9% | -24.1% | – |
| EPS Diluted | -0.3 | -0.5 | -0.36 | -0.29 |
| Weighted Avg Shares Out | 136 | 114 | 107 | 105 |
| Weighted Avg Shares Out Dil | 136 | 114 | 107 | 105 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $3 |
| Interest Expense | $13 | $13 | $12 | $12 |
| Depreciation & Amortization | $0 | $1 | $1 | $1 |
| EBITDA | -$27 | -$42 | -$26 | -$19 |
| % Margin | -167.1% | -220.6% | -111.5% | -111.4% |